Ocugen is redefining the future of vision through game-changing gene therapies with the potential to address significant, unmet medical needs. Our first-in-class, breakthrough modifier gene therapy platform presents a paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe.
We are turning purpose into action—delivering hope where none exists.
Guided by compassion and driven by passion, we put patients at the center of everything we do.
“The promise of helping to transform lives—that’s what drives the work I do at Ocugen. I am proud to be a member of our team of dedicated individuals, collaborating to find solutions to address unmet medical needs, in service for patients.”
— Thais McNeal, Head Government Affairs & Patient Advocacy
“Healthcare has always been in my DNA and it’s a sector that continues to show us how innovation can change peoples’ lives.”
— Dr. Shankar Musunuri, Chairman, CEO, and co-founder of Ocugen
“We want to offer hope. Not just for vision-related conditions, but for many diseases that seem hopeless.”
— Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development and Medical
“We remind ourselves that nothing is impossible with science; it’s just a matter of figuring things out.”
— Sree Kattala, Research Associate Scientist
We are shaping solutions to medical challenges with purpose and agility. Together, we are working to bring more therapeutic options to patients.
Learn About Our ProgressExplore how Ocugen is advancing a pipeline built on courage, innovation, and impact.
View Our Corporate Story